Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 27,848 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo and sham treatment Clear all

Conditions: Neuropathic Back Pain, Spinal Cord Injury
Interventions: Botulinum Toxin A, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteer
Interventions: ABBV-295, Placebo for ABBV-295; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Anaheim, California

Conditions: AIDS
Interventions: GSK Biologicals HIV Vaccine 732462, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 17
States / cities: Bakersfield, California • Long Beach, California • Washington D.C., District of Columbia + 13 more

Conditions: Hidradenitis Suppurativa
Interventions: Tulisokibart, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more

Conditions: Hyperlipidemias
Interventions: Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos; Combination Product · Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: secukinumab 150 mg, secukinumab 300 mg, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more

Conditions: Atopic Dermatitis
Interventions: Placebo, PF-04965842, PF04965842; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 52
States / cities: Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
Interventions: Resmetirom, Placebo Control; Drug
Lead sponsor: Naga P. Chalasani; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 7 more

Conditions: Osteoporosis
Interventions: Placebo, Green Tea Polyphenols (GTP), Placebo+Tai Chi (TC), GTP+TC; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: Female only
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Digestive Disease, Gut Health
Interventions: Probiotic, Placebo; Dietary Supplement · Other
Lead sponsor: Synbiotic Health; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Erectile Dysfunction
Interventions: Udenafil, Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 19 Years and older · Male only
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 40
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tempe, Arizona + 36 more

Conditions: Cancer Cachexia
Interventions: Macimorelin, Placebo; Drug
Lead sponsor: Garcia, Jose M., MD, PhD; Individual
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis, Hip
Interventions: Dexamethasone, Bupivacaine, Epinephrine, Lumbar Plexus Nerve Block, Saline; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: C-reactive Protein, Inflammation, Obesity, Oxidative Stress
Interventions: Vitamin C (ascorbic acid), Placebo tablet; Dietary Supplement
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Oakland, California

Conditions: Peripheral Artery Disease, Exercise, Intermittent Claudication, Nitric Oxide
Interventions: Supervised Treadmill Exercise, Attention Control, Nitrate-Rich Beetroot Juice + supervised exercise therapy, Placebo + supervised exercise therapy; Behavioral · Combination Product
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Depressive Disorder, Major
Interventions: vilazodone; Drug
Lead sponsor: Genaissance Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 15
States / cities: Los Alamitos, California • Newport Beach, California • Northridge, California + 12 more

Conditions: Chronic Kidney Disease
Interventions: Paricalcitol, Placebo; Drug
Lead sponsor: Amy Barton Pai; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Albany, New York

Conditions: Hypotension
Interventions: Phenylephrine bolus, phenylephrine infusion; Drug
Lead sponsor: IWK Health Centre; Other
Eligibility: 18 Years and older · Female only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Polymyalgia Rheumatica
Interventions: ABBV-154, Placebo, Glucocorticoid; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Jonesboro, Arkansas • Fullerton, California • Huntington Beach, California + 28 more

Conditions: Fibromyalgia
Interventions: Lymphatic Enhancement Technology (LET), Sham Lymphatic Enhancement Technology (LET); Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Microtia, Dysbiosis, Alcohol Drinking, HIV Infections, Cardiovascular Diseases
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autistic Disorder
Interventions: Donepezil HCl, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 8 Years to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Los Angeles, California • Whittier, California • Fort Myers, Florida + 8 more

Conditions: Alzheimer's Disease
Interventions: Curcumin C3 Complex; Dietary Supplement
Lead sponsor: John Douglas French Foundation; Other
Eligibility: 50 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Westwood, Los Angeles, California

Search by objective public record fields.

Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

Green Tea and Tai Chi for Bone Health

Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes

Treatment of Erectile Dysfunction II

Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia

Systemic Steroids for Peripheral Nerve Blocks

Obesity, Inflammation and Oxidative Stress

Response to Exercise and Nitric Oxide in PAD

Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response

Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo

Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154

LET for Fibromyalgia

Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

Donepezil HCl & Cognitive Deficits in Autism

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Curcumin in Patients With Mild to Moderate Alzheimer's Disease